CONTINUOUS SUBCUTANEOUS PUMP INFUSION OF SOMATOSTATIN ANALOGUE SMS 201‐995 VERSUS SUBCUTANEOUS INJECTION SCHEDULE IN ACROMEGALIC PATIENTS
- 1 September 1987
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 27 (3) , 297-306
- https://doi.org/10.1111/j.1365-2265.1987.tb01156.x
Abstract
Diurnal serum GH patterns were determined in 10 acromegalic patients before treatment, after 3 d continuous s.c. pump infusion and then after 3 d with three equal daily s.c. injections in both instances totalling 100 .mu.g/24 h. Subcutaneous injections (33 .mu.g) induced impressive suppression of serum GH lasting 3-6 h in eight patients followed by escape to pretreatment values before the next injection. In contrast, continuous infusion resulted in greater and more stable 24 h suppression to the levels reached at the nadir between injections. Suppression of mean 24 h serum GH below 5 ng/ml was achieved by pump treatment in four patients, while two patients had mean values between 5 ng/ml and 10 ng/ml. In four patients occasional or all levels were above 10 ng/ml (24 h average 12.4-102 ng/ml) implying either that adequate suppression by the SMS 201-995, was impossible during the 3 d pump infusion period, or that the dose administered was inadequate. Carbohydrate tolerance was unaffected in either regimen, indicating that reduction in insulin antagonistic hormones balanced inhibition of insulin release. Interestingly, and in contrast to somatostatin, SMS 201-995 did not inhibit TSH release. No untoward effects were observed at the moderate dosage and blood clinical chemistry was unchanged. Fairly constant diurnal serum SMS 201-995 values were obtained during pump infusion, while levels undulated inversely with serum GH during injection treatment. Average diurnal serum somatostatin-C immunoreactivity (all patients) decreased from 496 .+-. 129 (mean .+-. SD) to 385 .+-. 100 ng/ml (P < 0.003) during pump treatment and did not decrease further during the following 3 d injection treatment (363 .+-. 76 ng/ml). The normal adult mean is 179 .+-. 40 ng/ml. Computer tomographic (CT) scans of the sellar region were performed in all patients before and after the experimental week. Two patients had extracellular tumours whose size decreased from 8.2 to 4.1 cm3 and from 12.6 to 10.5 cm3. The results demonstrate that superior and stable suppression of GH secretion is obtained during continuous s.c. pump infusion of SMS 201-995.This publication has 17 references indexed in Scilit:
- Long-Term Treatment of Acromegaly with the Somatostatin Analogue SMS 201–995New England Journal of Medicine, 1985
- The Somatostatin Analog SMS 201-995 Induces Long-Acting Inhibition of Growth Hormone Secretion without Rebound Hypersecretion in Acromegalic Patients*Journal of Clinical Endocrinology & Metabolism, 1985
- LONG-ACTING AND SELECTIVE SUPPRESSION OF GROWTH HORMONE SECRETION BY SOMATOSTATIN ANALOGUE SMS 201-995 IN ACROMEGALYThe Lancet, 1984
- Computed tomography of sellar and parasellar lesionsClinical Radiology, 1983
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982
- Long-term treatment of acromegaly with bromocriptine.BMJ, 1977
- Ultrasensitive Radioimmunoassay for Direct Determination of Free Triiodothyronine Concentration in SerumScandinavian Journal of Clinical and Laboratory Investigation, 1975
- GROWTH HORMONE IN ACROMEGALYThe Lancet, 1973
- Some Actions of Growth Hormone Release Inhibiting FactorBMJ, 1973
- ACTION OF GROWTH-HORMONE-RELEASE INHIBITORY HORMONE IN HEALTHY MEN AND IN ACROMEGALYThe Lancet, 1973